Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists
Identifieur interne : 003125 ( Main/Exploration ); précédent : 003124; suivant : 003126Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists
Auteurs : Ji-Youn Kim [Corée du Sud] ; Eun Joo Chung [Corée du Sud] ; Seung Woo Park [Corée du Sud] ; Won Yong Lee [Corée du Sud]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-08.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Bromocriptine, Bromocriptine (adverse effects), Bromocriptine (therapeutic use), Cardiac valvular disease, Dopamine Agonists (adverse effects), Dopamine Agonists (therapeutic use), Dopamine agonist, Echocardiography, Ergot Alkaloids (adverse effects), Ergot derivatives, Heart Valve Diseases (chemically induced), Heart Valve Diseases (physiopathology), Humans, Middle Aged, Nervous system diseases, Parkinson Disease (drug therapy), Parkinson disease, Parkinson's disease, Pergolide, Pergolide (adverse effects), Pergolide (therapeutic use), Reference Values, Treatment, bromocriptine, pergolide, valvulopathy.
- MESH :
- chemical , adverse effects : Bromocriptine, Dopamine Agonists, Ergot Alkaloids, Pergolide.
- chemical , therapeutic use : Bromocriptine, Dopamine Agonists, Pergolide.
- chemically induced : Heart Valve Diseases.
- drug therapy : Parkinson Disease.
- physiopathology : Heart Valve Diseases.
- Adult, Aged, Aged, 80 and over, Echocardiography, Humans, Middle Aged, Reference Values.
Abstract
Valvular heart disease, associated with ergot derivative dopamine agonists, has been reported in patients with Parkinson's disease (PD). There are few comparative studies on the frequency, severity, and dose dependency of valvular disease associated with ergot derivatives. We analyzed these factors in 58 PD patients who were taking ergot derivatives (22 were taking bromocriptine and 36 were taking pergolide) and compared them with 20 age‐matched controls based on the two‐dimensional echocardiographic findings. Aortic, mitral, and tricuspid valvular thicknesses, as well as tenting areas and tenting distance of the mitral valve were measured. We also assessed the correlation between the cumulative or daily doses of ergot derivatives and each valvular parameter. There was no significant increase in the frequency of valvulopathy in the PD patients taking bromocriptine or pergolide. We identified a positive correlation between the daily dose of pergolide and the tenting area of the mitral valve (r = 0.385; P = 0.020). However, other valvular parameters were not found to correlate with the age, disease duration, treatment duration, or dosage of medication. Our study failed to uncover definitive harmful effects of ergot derivative dopamine agonists on cardiac valves; this is considering the relatively lower daily doses than other reported cases. To establish a dosage dependency with valvulopathy, a more detailed study with higher doses of ergot derivatives for longer duration of treatment may be needed. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.20931
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001E98
- to stream Istex, to step Curation: 001E98
- to stream Istex, to step Checkpoint: 001B84
- to stream PubMed, to step Corpus: 002C47
- to stream PubMed, to step Curation: 002C47
- to stream PubMed, to step Checkpoint: 002A33
- to stream Ncbi, to step Merge: 001687
- to stream Ncbi, to step Curation: 001687
- to stream Ncbi, to step Checkpoint: 001687
- to stream Main, to step Merge: 004438
- to stream PascalFrancis, to step Corpus: 001A29
- to stream PascalFrancis, to step Curation: 001292
- to stream PascalFrancis, to step Checkpoint: 001847
- to stream Main, to step Merge: 004942
- to stream Main, to step Curation: 003125
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists</title>
<author><name sortKey="Kim, Ji Oun" sort="Kim, Ji Oun" uniqKey="Kim J" first="Ji-Youn" last="Kim">Ji-Youn Kim</name>
</author>
<author><name sortKey="Chung, Eun Joo" sort="Chung, Eun Joo" uniqKey="Chung E" first="Eun Joo" last="Chung">Eun Joo Chung</name>
</author>
<author><name sortKey="Park, Seung Woo" sort="Park, Seung Woo" uniqKey="Park S" first="Seung Woo" last="Park">Seung Woo Park</name>
</author>
<author><name sortKey="Lee, Won Yong" sort="Lee, Won Yong" uniqKey="Lee W" first="Won Yong" last="Lee">Won Yong Lee</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:E865FACE23E317825FBD8E440267FCC66130CA6C</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.20931</idno>
<idno type="url">https://api.istex.fr/document/E865FACE23E317825FBD8E440267FCC66130CA6C/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001E98</idno>
<idno type="wicri:Area/Istex/Curation">001E98</idno>
<idno type="wicri:Area/Istex/Checkpoint">001B84</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Kim J:valvular:heart:disease</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16685692</idno>
<idno type="wicri:Area/PubMed/Corpus">002C47</idno>
<idno type="wicri:Area/PubMed/Curation">002C47</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002A33</idno>
<idno type="wicri:Area/Ncbi/Merge">001687</idno>
<idno type="wicri:Area/Ncbi/Curation">001687</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001687</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Kim J:valvular:heart:disease</idno>
<idno type="wicri:Area/Main/Merge">004438</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:06-0435109</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001A29</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001292</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001847</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Kim J:valvular:heart:disease</idno>
<idno type="wicri:Area/Main/Merge">004942</idno>
<idno type="wicri:Area/Main/Curation">003125</idno>
<idno type="wicri:Area/Main/Exploration">003125</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists</title>
<author><name sortKey="Kim, Ji Oun" sort="Kim, Ji Oun" uniqKey="Kim J" first="Ji-Youn" last="Kim">Ji-Youn Kim</name>
<affiliation wicri:level="3"><country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Chung, Eun Joo" sort="Chung, Eun Joo" uniqKey="Chung E" first="Eun Joo" last="Chung">Eun Joo Chung</name>
<affiliation wicri:level="3"><country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Park, Seung Woo" sort="Park, Seung Woo" uniqKey="Park S" first="Seung Woo" last="Park">Seung Woo Park</name>
<affiliation wicri:level="3"><country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lee, Won Yong" sort="Lee, Won Yong" uniqKey="Lee W" first="Won Yong" last="Lee">Won Yong Lee</name>
<affiliation wicri:level="3"><country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-08">2006-08</date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">8</biblScope>
<biblScope unit="page" from="1261">1261</biblScope>
<biblScope unit="page" to="1264">1264</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">E865FACE23E317825FBD8E440267FCC66130CA6C</idno>
<idno type="DOI">10.1002/mds.20931</idno>
<idno type="ArticleID">MDS20931</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Bromocriptine</term>
<term>Bromocriptine (adverse effects)</term>
<term>Bromocriptine (therapeutic use)</term>
<term>Cardiac valvular disease</term>
<term>Dopamine Agonists (adverse effects)</term>
<term>Dopamine Agonists (therapeutic use)</term>
<term>Dopamine agonist</term>
<term>Echocardiography</term>
<term>Ergot Alkaloids (adverse effects)</term>
<term>Ergot derivatives</term>
<term>Heart Valve Diseases (chemically induced)</term>
<term>Heart Valve Diseases (physiopathology)</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Nervous system diseases</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Pergolide</term>
<term>Pergolide (adverse effects)</term>
<term>Pergolide (therapeutic use)</term>
<term>Reference Values</term>
<term>Treatment</term>
<term>bromocriptine</term>
<term>pergolide</term>
<term>valvulopathy</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Bromocriptine</term>
<term>Dopamine Agonists</term>
<term>Ergot Alkaloids</term>
<term>Pergolide</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Bromocriptine</term>
<term>Dopamine Agonists</term>
<term>Pergolide</term>
</keywords>
<keywords scheme="MESH" qualifier="chemically induced" xml:lang="en"><term>Heart Valve Diseases</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Heart Valve Diseases</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Aged</term>
<term>Aged, 80 and over</term>
<term>Echocardiography</term>
<term>Humans</term>
<term>Middle Aged</term>
<term>Reference Values</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Bromocriptine</term>
<term>Cardiopathie valvulaire</term>
<term>Ergot dérivé</term>
<term>Parkinson maladie</term>
<term>Pergolide</term>
<term>Stimulant dopaminergique</term>
<term>Système nerveux pathologie</term>
<term>Traitement</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Valvular heart disease, associated with ergot derivative dopamine agonists, has been reported in patients with Parkinson's disease (PD). There are few comparative studies on the frequency, severity, and dose dependency of valvular disease associated with ergot derivatives. We analyzed these factors in 58 PD patients who were taking ergot derivatives (22 were taking bromocriptine and 36 were taking pergolide) and compared them with 20 age‐matched controls based on the two‐dimensional echocardiographic findings. Aortic, mitral, and tricuspid valvular thicknesses, as well as tenting areas and tenting distance of the mitral valve were measured. We also assessed the correlation between the cumulative or daily doses of ergot derivatives and each valvular parameter. There was no significant increase in the frequency of valvulopathy in the PD patients taking bromocriptine or pergolide. We identified a positive correlation between the daily dose of pergolide and the tenting area of the mitral valve (r = 0.385; P = 0.020). However, other valvular parameters were not found to correlate with the age, disease duration, treatment duration, or dosage of medication. Our study failed to uncover definitive harmful effects of ergot derivative dopamine agonists on cardiac valves; this is considering the relatively lower daily doses than other reported cases. To establish a dosage dependency with valvulopathy, a more detailed study with higher doses of ergot derivatives for longer duration of treatment may be needed. © 2006 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Corée du Sud</li>
</country>
<settlement><li>Séoul</li>
</settlement>
</list>
<tree><country name="Corée du Sud"><noRegion><name sortKey="Kim, Ji Oun" sort="Kim, Ji Oun" uniqKey="Kim J" first="Ji-Youn" last="Kim">Ji-Youn Kim</name>
</noRegion>
<name sortKey="Chung, Eun Joo" sort="Chung, Eun Joo" uniqKey="Chung E" first="Eun Joo" last="Chung">Eun Joo Chung</name>
<name sortKey="Lee, Won Yong" sort="Lee, Won Yong" uniqKey="Lee W" first="Won Yong" last="Lee">Won Yong Lee</name>
<name sortKey="Park, Seung Woo" sort="Park, Seung Woo" uniqKey="Park S" first="Seung Woo" last="Park">Seung Woo Park</name>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003125 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003125 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:E865FACE23E317825FBD8E440267FCC66130CA6C |texte= Valvular heart disease in Parkinson's disease treated with ergot derivative dopamine agonists }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |